TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25524125
Drug: Dermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal patch (control)
Study: 21872244
Drug: 600 μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μg of oral misoprostol
Study: 19485583
Drug: Supervisor focus
Normalized name: Ficus benghalensis bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervisor focus on adherence to treatment principles
Study: 17214933
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese herbal medicine (CM) including Glucosidorum Tripterygii Totorum Tablet and syndrome differentiation treatment
Study: 17214933
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) including voltaren extended action tablet, methotrexate, and sulfasalazine
Study: 11319627
Drug: Active Ma
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - ACTIVE MAUVE (135)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Ma Huang/Guarana (72 mg/day ephedrine alkaloids and 240 mg/day caffeine)
Study: 24075206
Drug: Less Invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less Invasive Surfactant Administration (LISA)
Study: 19083472
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (WY) 15 g
Study: 19083472
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids (EAA) 6.72 g
Study: 19083472
Drug: Nonessential amino
Normalized name: Nonessential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonessential amino acids (NEAA) 7.57 g
Study: 16510062
Drug: Topical allylamine
Normalized name: vanillylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical allylamine antifungals (naftifine, terbinafine, butenafine)
Study: 16510062
Drug: Topical azole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical azole antifungals (clotrimazole, econazole, ketoconazole, oxiconazole, miconazole, sulconazole)
Study: 10894274
Drug: Lamivudine therapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine therapy for 44-52 weeks
Study: 1376362
Drug: Hydromorphone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (5 and 10 mg)
Study: 28841028
Drug: Pre-hospital ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-hospital ticagrelor treatment
Study: 28969431
Drug: HIV-DNA 600
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-DNA 600 μg (n=10)
Study: 28969431
Drug: HIV-DNA 1200
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-DNA 1200 μg (n=10)
Study: 24295662
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality using chemotherapy and concurrent radiation
Study: 23154315
Drug: Self-administered paper
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered paper interview
Study: 2145744
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (no thrombolytic therapy)
Study: 28063938
Drug: BCV 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCV 100 mg (2 mg/kg if <50 kg) twice weekly (BIW)
Study: 28063938
Drug: BCV 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCV 200 mg (4 mg/kg if <50 kg) once weekly (QW)
Study: 19706085
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide 0.01% oil applied twice daily for 4 weeks
Study: 7805700
Drug: Piroxicam beta‐cyclodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam beta‐cyclodextrin (tablet and sachet formulations)
Study: 3815764
Drug: Taurine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (6 g for 7 days)
Study: 12668787
Drug: Combined inhalation
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined inhalation of nitric oxide and oxygen
Study: 7548496
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg once a day for 3 days)
Study: 7548496
Drug: Tetracycline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (500 mg four times a day for 3 days)
Study: 1940257
Drug: Silibinin 100
Normalized name: Silibinin
DrugBank: Silibinin (DB09298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silibinin 100 mg/kg body weight i.p. for 7 days
Study: 1940257
Drug: Silibinin 50
Normalized name: Silibinin
DrugBank: Silibinin (DB09298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silibinin 50 mg/kg body weight i.p. for 7 days
Study: 28106354
Drug: Ropivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (20 mL of 0.5%) + Dexmedetomidine (1 µg/kg)
Study: 28106354
Drug: Ropivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (20 mL of 0.5%)
Study: 17033146
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (EBM)
Study: 11680444
Drug: Estradiol therapy
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol therapy (1 mg of estradiol-17beta per day)
Study: 30304656
Drug: Delayed strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed strategy for renal-replacement therapy (after a delay of 48 hours if renal recovery had not occurred)
Study: 30304656
Drug: Delayed strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed strategy for renal-replacement therapy
Study: 17017821
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (STS) 6 mg/24 hours to 12 mg/24 hours
Study: 10997967
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no cytoreductive therapy)
Study: 19994680
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Flunarizine hydrochlorid capsules)
Study: 11282668
Drug: Intranasal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal lidocaine (1 mL of 4% lidocaine)
Study: 8310996
Drug: 22-44 g
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-44 g pyruvate (n = 17)
Study: 3335988
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg metoclopramide orally, 40‐45 min before procedure
Study: 10671804
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy (n = 56)
Study: 27499378
Drug: suPAR levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: suPAR levels (measured in log2 ng/mL)
Study: 7536999
Drug: iloprost intravenously
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iloprost intravenously for 6 hours per day (mean dose: 1.7 ng/kg/min)
Study: 7536999
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no trial therapy)
Study: 7536999
Drug: iloprost treatment
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iloprost treatment
Study: 31112954
Drug: Desidustat 100
Normalized name: Desidustat
DrugBank: Desidustat (DB16135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desidustat 100 mg
Study: 31112954
Drug: Desidustat 150
Normalized name: Desidustat
DrugBank: Desidustat (DB16135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desidustat 150 mg
Study: 31112954
Drug: Desidustat 200
Normalized name: Desidustat
DrugBank: Desidustat (DB16135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desidustat 200 mg
Study: 28851409
Drug: ECG device
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECG device (Kardia Mobile) recording twice daily for 1 year
Study: 10396713
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.5% bupivacaine (group BIB)
Study: 10396713
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of oxycodone in 10 ml of saline (group OIB)
Study: 10396713
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of oxycodone intramuscularly (group OIM)
Study: 7747715
Drug: Chemotherapy (Adriamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Adriamycin alone)
Study: 26017589
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment
Study: 29049211
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg 24 hours preoperative administration (EPEA)
Study: 29049211
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg 1 hour preoperative administration (PEA)
Study: 29049211
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg 4 hours postoperative administration (POA)
Study: 27056950
Drug: Pritelivir treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pritelivir treatment (dosage not specified) for 28 days
Study: 21961887
Drug: New Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Paracetamol pediatric suspension (PPS)
Study: 16683415
Drug: Adjuvant platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant platinum-based chemotherapy
Study: 19258948
Drug: Observation after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation after surgical treatment
Study: 12734607
Drug: Molsidomine 16
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 16 mg once-a-day
Study: 15676171
Drug: Molsidomine 8
Normalized name: molsidomine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 8 mg twice-a-day
Study: 7655964
Drug: Pulse spray
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse spray thrombolysis with 0.33 mg/ml rt‐PA injected as a bolus of 0.2 ml
Study: 7655964
Drug: Conventional thrombolysis
Normalized name: THROMBOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional thrombolysis with 0.05 mg/ml rt‐PA infused at a rate of 10 ml/h
Study: 19821962
Drug: Supplemental fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental fluid (prescribed plus 10 mL/kg) for 5 days
Study: 14993586
Drug: Fiber (glucomannan)
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber (glucomannan) 100 mg/kg body weight daily (max 5 g/day) for 4 weeks
Study: 8260241
Drug: 3M chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3M chemotherapy alone
Study: 3631731
Drug: Greater level
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater level of effort while breathing room air (25.0 ± 0.4 degrees C, 15.7 ± 0.2 mg H2O/L)
Study: 20080017
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg or 8 mg in adults; 0.15 mg/kg in children
Study: 20080017
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg in adults
Study: 12586255
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg plus lovastatin (10, 20, or 40 mg)
Study: 1662877
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg or 750 mg b.i.d.
Study: 6789358
Drug: Reserpine at
Normalized name: Reserpine
DrugBank: Reserpine (DB00206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reserpine at doses of 0.75‐1.5 mg daily
Study: 6789358
Drug: Alpha‐methyldopa at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha‐methyldopa at doses of 750‐1,500 mg daily
Study: 22344322
Drug: Multivalent polyclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivalent polyclonal antibody preparation (PAP) at 10 mL·d(‐1)
Study: 22344322
Drug: Monensin (MON)
Normalized name: Monensin
DrugBank: Monensin (DB11430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monensin (MON) at 300 mg·d(‐1)
Study: 22344322
Drug: Crossbred yearling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossbred yearling bulls (TC and CC)
Study: 30474791
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol (1000 mg)
Study: 22385032
Drug: Prescription aluminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription aluminum chloride (6.5%) antiperspirant
Study: 20491723
Drug: Motivation Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivation Enhancement Treatment (MET)
Study: 7036282
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with levamisole
Study: 21617197
Drug: Low-dose sirolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sirolimus (Low-SRL)
Study: 21617197
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus (Low-Tac)
Study: 21617197
Drug: Standard-dose cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cyclosporine (Stand-CsA) and Low-dose cyclosporine (Low-CsA)
Study: 19020496
Drug: Erythromycin (as
Normalized name: erythromycin (as lactobionate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (as a prototypical irreversible inhibitor of CYP3A)
Study: 17870625
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural bupivacaine and morphine
Study: 15356075
Drug: Intranasal atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal atrial natriuretic peptide (ANP) 1 mg
Study: 9069306
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (CT) plus radiation therapy (RT)
Study: 8450399
Drug: Pharmacological dose
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological dose of recombinant human growth hormone (5.0 mg, every other day)
Study: 8450399
Drug: Physiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological dose of recombinant human growth hormone (2.5 mg, every other day)
Study: 3528672
Drug: G 115
Normalized name: penicillin G benzathine 115 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: G 115 (100 mg twice a day for 12 weeks)
Study: 25708488
Drug: Fluconazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (6 mg/kg)
Study: 27129005
Drug: Omeprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (60 mg)
Study: 27129005
Drug: Ritonavir (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (30 mg)
Study: 21901480
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day isoflavones (aglycone equivalents)
Study: 17497593
Drug: BCAA drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA drink containing 2 g of BCAA and 0.5 g of Arg
Study: 11684077
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of atorvastatin
Study: 16253583
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of pravastatin
Study: 15023882
Drug: Clopidogrel (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (375 mg loading dose, followed by 75 mg/d for at least 3 months)
Study: 7771954
Drug: Lovastatin (L)
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin (L) 20 mg/day
Study: 29258695
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT)
Study: 27846913
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) alone
Study: 27630213
Drug: Understanding that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Understanding that psychological treatment was not offered
Study: 27630213
Drug: Incorrect indication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorrect indication of participation replacing current psychological treatment
Study: 26351776
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 supplementation that raised 25(OH)D levels to ≥32 ng/mL
Study: 23512062
Drug: Eritoran (105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eritoran (105 mg total over 6 days)
Study: 20483152
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy
Study: 8749780
Drug: Low or
Normalized name: Milkflow oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low or standard dose chemotherapy
Study: 8749780
Drug: Different treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different treatment regimens
Study: 2293142
Drug: Codeine 60
Normalized name: codeine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 60 mg plus paracetamol 1 g 3 times daily
Study: 30630183
Drug: Topical Lactococcus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Lactococcus lactis emulsion applied once daily for 4 days on reconstructed human epidermis
Study: 26358536
Drug: Parent and
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent and child family-based treatment (FBT)
Study: 15210457
Drug: Narrowband UV-B
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband UV-B (NB-UV-B) phototherapy, 3 times a week for either 60 treatments or 6 months
Study: 19774117
Drug: MA‐ES 625
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA‐ES 625 mg/5 mL with a high-calorie, high-fat meal
Study: 19774117
Drug: MAOS 800
Normalized name: Mao cang zhu rhizome
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAOS 800 mg/20 mL
Study: 15570274
Drug: Ligation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligation and vein stripping (S and L)
Study: 10683000
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg) plus vitamin B6 (250 mg) daily for 2 years
Study: 15681958
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Patch
Study: 25976467
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) treatment (dosage > 20 mg/kg/day)
Study: 18979086
Drug: 25-g glucose
Normalized name: glucose 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-g glucose drink
Study: 31852268
Drug: bDMARDs (biologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: bDMARDs (biologic disease-modifying anti-rheumatic drugs)
Study: 31852268
Drug: csDMARDs (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: csDMARDs (conventional synthetic disease-modifying anti-rheumatic drugs)
Study: 31852268
Drug: cyclosporine and
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine and TNF inhibitors
Study: 27856142
Drug: Onartuzumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onartuzumab (15 mg/kg intravenously every 3 weeks) in combination with bevacizumab-based chemotherapy
Study: 27856142
Drug: Onartuzumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onartuzumab (15 mg/kg intravenously every 3 weeks) in combination with pemetrexed-based chemotherapy
Study: 27856142
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with bevacizumab-based chemotherapy
Study: 27856142
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with pemetrexed-based chemotherapy
Study: 22366196
Drug: Aclidinium 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium 200 μg, 400 μg, 800 μg, twice daily for 7 days
Study: 22366196
Drug: Aclidinium (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium (all doses), twice daily for 7 days
Study: 18979100
Drug: Combined intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined intra-arterial chemotherapy
Study: 2339013
Drug: Amitriptyline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline + psychotherapy (N = 26), twelve 45 min weekly sessions
Study: 31358922
Drug: Intravitreal Conbercept
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Conbercept injections (three loading doses and thereafter pro re nata [PRN])
Study: 31358922
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 months' sham injection, then one Conbercept injection at month 4 and thereafter PRN)
Study: 11719888
Drug: Placebo (maltodextrine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrine, 4 times daily for 5 days)
Study: 2465530
Drug: Carbamazepine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (800 mg/day)
Study: 29102818
Drug: Paroxetine, 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine, 12 weeks of open treatment
Study: 21985070
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg day(-1)
Study: 15515816
Drug: ccHRT (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ccHRT (50 mg of 17beta‐estradiol and 5 mg of oral progesterone)
Study: 11273923
Drug: Rectal acetaminophen
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetaminophen 10 mg/kg